Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
about
Modern natural products drug discovery and its relevance to biodiversity conservationOptimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.Co-administration of betulinic acid and methamphetamine causes toxicity to dopaminergic and serotonergic nerve terminals in the striatum of late adolescent ratsSynthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variantsDesign, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity.New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant VirusDesign, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.Influence of betulinic acid on lymphocyte subsets and humoral immune response in mice.Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
P2860
Q29353836-8E9F8860-A0C5-42A2-BF52-FB36E9153B02Q33860320-9F523AF2-AAA5-41F2-95AB-F075B3EC424DQ34428204-DE596B72-1958-40C6-B5CF-C557B8C3D5EDQ36185528-FB73C952-B019-4366-A638-513CDDA4C592Q36292585-C962833B-5122-4DB9-8718-F7DCE3162D37Q36616220-11ADC474-6264-463F-9D4F-B7D7B29AF05EQ36691642-16CD6B1C-AF5E-40C4-94FD-BB6258A8C393Q37550710-C91E1E5E-8CC8-45C7-A2B4-9E129E210B70Q39635884-47D38693-485E-4D76-9A9B-3C903ED84FC6Q40218320-E75CF847-51A0-4D8D-AF8F-02727F20E4C4Q42732016-514820A4-9814-4FC7-99B4-2B3DE89B033DQ50506090-C8F8E9C5-94DF-4269-8D64-AEE3DE8EF640Q52596192-785B5123-1D3A-43B8-A32E-74D66E1563B7
P2860
Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
@en
Betulinic acid derivatives as human immunodeficiency virus type 2
@nl
type
label
Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
@en
Betulinic acid derivatives as human immunodeficiency virus type 2
@nl
prefLabel
Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
@en
Betulinic acid derivatives as human immunodeficiency virus type 2
@nl
P2093
P2860
P356
P1476
Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
@en
P2093
Chin-Ho Chen
Keduo Qian
Kuo-Hsiung Lee
Weihong Lai
P2860
P304
P356
10.1021/JM9004253
P407
P577
2009-12-01T00:00:00Z